Loading video...

Video Failed to Load

Go Home

Dr. Benjamin Schrank explains his recent research on a first-in-class antibody-drug conjugate that is designed to trigger an immune response, as a complementary strategy to radiation therapy. Read more: Benjamin Schrank, MD, PhD #ASTRO24 #EndCancer

11,282 views • 1 year ago •via X (Twitter)

4 Comments

Betty Y.S. Kim, MD, PhD, FRCSC, FAIMBE's profile picture
Betty Y.S. Kim, MD, PhD, FRCSC, FAIMBE1 year ago

@BenjaminSchrank @BenjaminSchrank is without a doubt one of the very best physician scientist trainee I have ever encountered. Quadruple threat: great scientist, leadership skills, gifted educator and super kind/humble. Truly exceptional. He’s also on the job market. So proud!

Benjamin Schrank, MD, PhD's profile picture
Benjamin Schrank, MD, PhD1 year ago

Thankful to @BettyKimLab and @wenjiang_nano for their continued mentorship and support!

Raffaele Di Giacomo, PhD's profile picture
Raffaele Di Giacomo, PhD1 year ago

Dr. Schrank's research on the antibody-drug conjugate sounds promising, especially as a complement to radiation therapy. By triggering an immune response, it could enhance the overall effectiveness of cancer treatments – potentially improving patient outcomes. How does this conjugate specifically interact with the immune system compared to other immunotherapies? For those interested in more detailed biomedical insights or reviews, check out – your one-stop platform for every biomedical question. #Medicine #CancerResearch #Immunotherapy

Mother of Swans's profile picture
Mother of Swans1 year ago

@BenjaminSchrank 👏 LFG! Help me live! #NSCLC #EGFR #OligoBrainMets

Related Videos